Matveev B P, Gorbunova V A, Smirnova N B, Zhumagazin Zh D, Bukharkin B V, Orel N F
Urol Nefrol (Mosk). 1996 May-Jun(3):34-6.
A 22% response rate was achieved in clinical trials of Russian drug cycloplatam in disseminated and hormone-resistant cancer of the prostate. In 80% of cases the drug has improved quality of life of patients with prostatic cancer stage III and IV. Antitumor effect and low toxicity make cycloplatam applicable in combined therapy of prostatic cancer.
俄罗斯药物环铂在前列腺播散性和激素抵抗性癌症的临床试验中实现了22%的缓解率。在80%的病例中，该药物改善了III期和IV期前列腺癌患者的生活质量。环铂的抗肿瘤作用和低毒性使其适用于前列腺癌的联合治疗。
